Regeneron (REGN) Tops Q2 EPS by 75c
Regeneron (NASDAQ: REGN) reported Q2 EPS of $5.45, $0.75 better than the analyst estimate of $4.70. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.56 billion.
- Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to $5.45 versus second quarter 2017
- Second quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 8% to $992 million versus second quarter 2017 and second quarter 2018 EYLEA global net sales(1) increased 13% to $1.66 billion versus second quarter 2017
- Positive results reported from Phase 3 trial of Dupixent® (dupilumab) in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
GUIDANCE:
The Company's updated full year 2018 financial guidance consists of the following components:
Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses | $455 million–$485 million (previously $450 million–$485 million) |
Non-GAAP unreimbursed R&D(2)(4) | $1.210 billion–$1.260 billion (previously $1.230 billion–$1.310 billion) |
Non-GAAP SG&A(2)(4) | $1.340 billion–$1.390 billion (previously $1.325 billion–$1.395 billion) |
Effective tax rate | 13%–16% (previously 15%–18%) |
Capital expenditures | $410 million–$450 million (previously $420 million–$480 million) |